Bifogade filer
NET ASSET VALUE – 30 November 2024
Kurs
-2,14%
Kurs
-2,14%
Open
49,11
High
49,52
Low
47,70
Close
48,93
Kursutveckling under dagen för detta pressmeddelande
(SEK).
Likviditet
2,30 MSEK
Likviditet
2,30 MSEK
Rel. mcap
0,06%
Antal aktier
46 996
Likviditet under dagen för detta pressmeddelande
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Flerie AB via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Ett email har skickats till adressen, bekräfta det för att slutföra prenumerationen.
Du har prenumererat
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Kalender
| Tid* | ||
| 2025-05-14 | N/A | Årsstämma |
| 2025-01-22 | 08:00 | Bokslutskommuniké 2024 |
| 2024-10-16 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-17 | - | Kvartalsrapport 2024-Q2 |
| 2024-07-12 | - | Split FLERIE 100:1 |
| 2024-05-14 | - | Årsstämma |
| 2024-05-08 | - | X-dag ordinarie utdelning FLERIE 0.00 SEK |
| 2024-04-15 | - | Kvartalsrapport 2024-Q1 |
| 2024-01-24 | - | Bokslutskommuniké 2023 |
| 2023-11-28 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-24 | - | Årsstämma |
| 2023-05-24 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-08 | - | X-dag ordinarie utdelning FLERIE 0.00 SEK |
| 2023-02-23 | - | Bokslutskommuniké 2022 |
| 2022-11-23 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-26 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-02 | - | X-dag ordinarie utdelning FLERIE 0.00 SEK |
| 2022-06-01 | - | Årsstämma |
| 2022-05-16 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-23 | - | Bokslutskommuniké 2021 |
| 2021-11-24 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-25 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-04 | - | X-dag ordinarie utdelning FLERIE 0.00 SEK |
| 2021-06-03 | - | Årsstämma |
| 2021-05-05 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2021-01-12 | - | Extra Bolagsstämma 2020 |
| 2020-11-25 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-26 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-07 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-21 | - | X-dag ordinarie utdelning FLERIE 0.00 SEK |
| 2020-04-20 | - | Årsstämma |
| 2020-02-20 | - | Bokslutskommuniké 2019 |
| 2019-11-27 | - | Kvartalsrapport 2019-Q3 |
| 2019-10-09 | - | Extra Bolagsstämma 2019 |
| 2019-08-15 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-07 | - | X-dag ordinarie utdelning FLERIE 0.00 SEK |
| 2019-05-06 | - | Årsstämma |
| 2019-05-06 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-20 | - | Bokslutskommuniké 2018 |
| 2018-11-19 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-28 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-25 | - | X-dag ordinarie utdelning FLERIE 0.00 SEK |
| 2018-05-24 | - | Årsstämma |
| 2018-05-17 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-26 | - | Bokslutskommuniké 2017 |
| 2017-11-17 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-25 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-31 | - | X-dag ordinarie utdelning FLERIE 0.00 SEK |
| 2017-05-30 | - | Årsstämma |
| 2017-05-30 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-27 | - | Bokslutskommuniké 2016 |
| 2016-11-22 | - | Kvartalsrapport 2016-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2024-12-03 08:00:00
On the 30 November 2024 Flerie AB's Net Asset Value (NAV) was SEK 4,206 million and NAV per share was SEK 53.88.
Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 42% | 486 | 6.23 | 11.6% |
| Xspray Pharma | 18% | 269 | 3.44 | 6.4% |
| KAHR Medical | 31% | 206 | 2.64 | 4.9% |
| Empros Pharma | 79% | 204 | 2.62 | 4.9% |
| Atrogi | 37% | 176 | 2.25 | 4.2% |
| Lipum | 57% | 171 | 2.19 | 4.1% |
| Microbiotica | 11% | 138 | 1.77 | 3.3% |
| Geneos Therapeutics | 12% | 105 | 1.34 | 2.5% |
| Xintela | 56% | 104 | 1.34 | 2.5% |
| Mendus | 24% | 101 | 1.30 | 2.4% |
| Toleranzia | 66% | 97 | 1.25 | 2.3% |
| EpiEndo Pharmaceuticals | 9% | 57 | 0.73 | 1.4% |
| Synerkine Pharma | 43% | 53 | 0.68 | 1.3% |
| AnaCardio | 19% | 52 | 0.66 | 1.2% |
| Egetis Therapeutics | 2% | 38 | 0.49 | 0.9% |
| Buzzard Pharmaceuticals | 14% | 29 | 0.37 | 0.7% |
| Vitara Biomedical | 8% | 29 | 0.37 | 0.7% |
| Sixera Pharma | 24% | 27 | 0.35 | 0.6% |
| Alder Therapeutics | 21% | 17 | 0.22 | 0.4% |
| Amarna Therapeutics | 58% | 12 | 0.15 | 0.3% |
| Strike Pharma | 16% | 9 | 0.11 | 0.2% |
| Total | 2,380 | 30.49 | 56.6% | |
| Commercial Growth | ||||
| NorthX Biologics | 92% | 189 | 2.42 | 4.5% |
| Symcel | 31% | 169 | 2.16 | 4.0% |
| Provell Pharmaceuticals | 72% | 78 | 0.99 | 1.8% |
| Chromafora | 31% | 73 | 0.93 | 1.7% |
| Nanologica | 43% | 63 | 0.81 | 1.5% |
| A3P Biomedical | 8% | 42 | 0.54 | 1.0% |
| Frontier Biosolutions | 2% | 19 | 0.24 | 0.5% |
| Bohus Biotech | 45% | 17 | 0.21 | 0.4% |
| Total | 649 | 8.31 | 15.4% | |
| Limited Partnerships, total | 92 | 1.18 | 2.2% | |
| Assets related to Portfolio companies | 299 | 3.84 | 7.1% | |
| Other assets and liabilities | 785 | 10.06 | 18.7% | |
| Net asset value | 4,206 | 53.88 | 100.0% | |
* indirect shares in Provell Pharmaceuticals
For more information:
Ted Fjällman, CEO
Email: ir@flerie.com
Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com
Attachments
NET ASSET VALUE – 30 November 2024